Welcome to our dedicated page for Veracyte SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
Veracyte Inc reported beneficial ownership by Vanguard Portfolio Management LLC. Vanguard Portfolio Management beneficially owns 4,512,852 shares of Veracyte common stock, representing 5.67% of the class. The filing shows 68,122 shares with sole voting power and 4,512,852 shares with sole dispositive power. The filing is signed by Ashley Grim on 04/29/2026.
Veracyte, Inc. is asking stockholders to vote at a virtual Annual Meeting on June 10, 2026. They will elect nine directors for one-year terms, ratify Ernst & Young LLP as auditor, hold an advisory vote on executive pay, and vote on expanding the 2023 Equity Incentive Plan.
The equity plan amendment would add 3,500,000 shares to the plan, on top of 9,704,039 shares available as of March 31, 2026, supporting continued stock-based compensation. The board is majority independent with an independent chair, fully independent committees, majority voting for uncontested elections, clawback policies, and extensive ESG and risk-oversight practices.
Haas Kevin Richard reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. Chief Dev and Tech Officer Kevin Richard Haas received a grant of 44,221 shares of Common Stock on April 10, 2026 as equity compensation. These are restricted stock units awarded at no cash cost to him.
The RSUs vest 25% on June 2, 2027, with the remaining portion vesting in equal 1/16 increments each quarter thereafter, subject to his continued employment on each vesting date. After this grant, he holds 44,221 shares directly according to the filing.
Veracyte Inc. ownership filing: The Vanguard Group filed an amendment to its Schedule 13G/A reporting 0 shares beneficially owned and 0% of common stock following an internal realignment.
The filing states certain Vanguard subsidiaries will report separately in reliance on SEC Release No. 34-39538 (January 12, 1998), and that Vanguard no longer is deemed to beneficially own securities held by those subsidiaries. The amendment is signed by Vanguard's Head of Global Fund Administration on 03/27/2026.
VERACYTE, INC. filed an initial insider ownership report for Kevin Richard Haas, who serves as Chief Development and Technology Officer. This Form 3 establishes his status as a reporting officer under SEC rules. The filing does not list any buy, sell, or other share transactions, focusing instead on his reporting obligation as a company insider.
Veracyte, Inc. appointed Dr. Kevin Haas, 40, as Chief Development and Technology Officer, effective March 24, 2026. He previously served as Chief Technology Officer and in senior technology and bioinformatics roles at Myriad Genetics and its women’s health business.
Under his offer letter dated March 13, 2026, Dr. Haas will receive an initial annual base salary of $500,000 and will be eligible for an annual performance-based cash bonus targeted at 55% of eligible annual earnings, with his 2026 bonus prorated based on his start date.
He is also slated to receive a restricted stock unit award with a target value of $1,500,000 vesting over four years and a performance-based restricted stock unit award with a target value of $1,500,000, subject to performance objectives and continued service, all under Veracyte’s 2023 Equity Incentive Plan.
Wygant Jonathan reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. reported that its VP and Chief Accounting Officer, Jonathan Wygant, received an equity award in the form of 10,525 shares of common stock on March 6, 2026. The shares were granted at no cash cost to him as part of compensation.
According to the award terms, these restricted stock units vest 25% on March 2, 2027, then 1/16 of the grant vests each quarter after that date, subject to his continued employment on each vesting date. Following this award, he directly holds 45,434 shares of Veracyte common stock.
McGuire Annie reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. reported that SVP and General Counsel Annie McGuire received two equity grants of common stock on March 6, 2026, both at no cash cost to her. Following these awards, she directly holds 153,912 shares.
The first grant of 32,892 restricted stock units vests 25% on March 2, 2027 and then 1/16 each quarter, subject to her continued employment on each vesting date. The second grant of 26,314 restricted stock units vests in full on the first anniversary of the grant, also contingent on continued employment.
Febbo Phillip G. reported acquisition or exercise transactions in this Form 4 filing.
Veracyte, Inc. reported that Chief Scientific & Med Officer Phillip G. Febbo received equity awards in the form of common stock on March 6, 2026. He was granted 29,603 shares and an additional 6,578 shares, both at no cash cost to him.
According to the footnotes, the first award, structured as restricted stock units, vests 25% on March 2, 2027 and then 1/16 each quarter, subject to continued employment. The second award vests in full on the first anniversary of the grant date, also contingent on his continued employment. Following these grants, he directly owns 153,527 shares of Veracyte common stock.